ARHP members are honored with awards for research, education, advocacy, and patient care in rheumatology
Search results for: Biologics
2013 ACR/ARHP Annual Meeting: Rheumatologists In the Spotlight
ACR members honored with awards for service, research, and mentorship in rheumatology
2013 ACR/ARHP Annual Meeting: The Rheumatoid Arthritis Treatment Debate
Discussion by rheumatologists on the merits of biologics vs. triple therapy for patients with RA lends insight into therapeutic alternatives
2013 ACR/ARHP Annual Meeting: Rheumatology Year in Review
Progress in treatments for pediatric rheumatic diseases, collaborative clinical trials, and personalized therapeutic approaches highlight the past year in rheumatology
Time Is Right to Join RheumPAC
We need your help building relationships with Congressional leaders to advance patient care, support research, and promote value of rheumatology
Researchers Look for Therapeutic Clues to Sjögrens Syndrome in Neural Pathways
Beyond biologic agents, scientists study cytokines, chemokines, and the interface between inflammatory and neural/secretory pathways
EULAR 2013: New RA Recommendations Address Combination Therapy Concerns
Guidelines give greater nod to use of combination conventional disease-modifying antirheumatic drugs (DMARDs) for rheumatoid arthritis, leave monotherapy with methotrexate as acceptable first-line treatment
EULAR 2013: Drugs New and Old Could Treat Spondylarthropies
Nonsteroidal anti-inflammatory drugs (NSAIDs) might still have a role in treating axial spondylarthritis, but other drugs, therapies are being explored
EULAR 2013: Emerging Imaging Methods in Spondylarthritis Have Advantages and Flaws
New technologies from diffusion-weighted imaging to ultrasonography are being studied and refined, but much is yet to be understood
When Will Generic Biologic Drugs Become Commercially Available?
Biosimilars are challenging to produce, but progress is being made
- « Previous Page
- 1
- …
- 57
- 58
- 59
- 60
- 61
- …
- 70
- Next Page »